CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
23 hedge funds and large institutions have $3.29M invested in CASI Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 2 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.93% less ownership
Funds ownership: 14.61% → 13.67% (-0.93%)
4% less funds holding
Funds holding: 24 → 23 (-1)
82% less capital inflows, than outflows
Capital inflows: $51.2K | Capital outflows: $288K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$47.1K |
| 2 |
Tower Research Capital (TRC)
New York
|
+$2.36K |
| 3 |
Renaissance Technologies
New York
|
+$992 |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$347 |
| 5 |
WPA
West Paces Advisors
Atlanta,
Georgia
|
+$198 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$227K |
| 2 |
Prudential Financial
Newark,
New Jersey
|
-$29K |
| 3 |
WSCM
Wellington Shields Capital Management
New York
|
-$24K |
| 4 |
Morgan Stanley
New York
|
-$4.03K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.31K |
CASI Hedge Fund Activity: Q4 2022 in Review
23 of the 6,241 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q4 2022, worth a combined $3.29M — down 36% from $5.17M a quarter earlier.
Fund positioning in CASI was balanced in Q4 2022: 2 funds opened new positions, 2 closed out, 8 added to existing stakes and 5 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $47.1K. The largest seller was Federated Hermes, cutting an estimated $227K.
- 23 institutional investors held CASI Pharmaceuticals (CASI) as of Q4 2022, down from 24 in Q3 2022.
- Funds reported $3.29M of CASI Pharmaceuticals stock for Q4 2022, down 36% quarter-over-quarter.
- 2 funds opened new CASI Pharmaceuticals positions in Q4 2022 and 2 closed out, a net change of 0 holders.
- The largest CASI Pharmaceuticals buyer in Q4 2022 was Susquehanna International Group, an estimated $47.1K added.
- The largest CASI Pharmaceuticals seller in Q4 2022 was Federated Hermes, an estimated $227K sold.
Based on aggregated 13F filings for Q4 2022.